Headlines about Covance (NYSE:CVD) have been trending positive on Sunday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Covance earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned news articles about the healthcare company an impact score of 91 out of 100, meaning that recent media coverage is extremely likely to have an impact on the stock’s share price in the immediate future.
COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/07/30/covance-nysecvd-receiving-positive-media-coverage-analysis-shows-updated-updated-updated.html.
Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.
Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.